News - HRD - LARVOL VERI

IdentifiHR predicts homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression. (PubMed, Commun Med (Lond))

IdentifiHR is an accurate model to predict HR status in HGSC. It is available as an open source R package, empowering researchers to robustly classify HR status when only transcriptomic sequencing data is available.

5 days ago

Journal • BRCA Biomarker

HRD (Homologous Recombination Deficiency)

HRD

Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort. (PubMed, JCO Precis Oncol)

HRD defines a biologically distinct subset of skin cancers and is not predictive of ICI response or improved outcomes. The high prevalence of HRD in acral and mucosal melanoma highlights the need to investigate HRD-directed therapies strategies in this distinct cohort, such as poly (ADP-ribose) polymerase inhibitors or platinum-based therapies.

5 days ago

Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)

MSI-H/dMMR • HRD

Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial. (PubMed, JCO Precis Oncol)

HRD status, KELIM, and TILs are key independent biomarkers in advanced OC. CCNE1 amplifications, although typically associated with platinum resistance, were linked to moderate chemotherapy sensitivity, defining an intermediate prognostic subgroup.

5 days ago

P2 data • Journal • BRCA Biomarker

HRD (Homologous Recombination Deficiency) • CCNE1 (Cyclin E1)

HRD

nintedanib

EFFORT: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)

P2, N=96, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

6 days ago

Trial completion date • Trial primary completion date

HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)

HRD • BRCA mutation

Lynparza (olaparib) • adavosertib (AZD1775) • ceralasertib (AZD6738)

Assessing the association between homologous recombination deficiency scores and treatment response in localized and metastatic prostate cancer. (PubMed, J Pathol Clin Res)

Molecular characterization showed that higher homologous recombination deficiency scores were associated with higher alteration rates in genes such as BRCA2, CDK12, MYC, and PTEN. This study reveals that higher homologous recombination deficiency scores are associated with unfavorable treatment efficacy of radical prostatectomy in localized prostate cancer and of androgen receptor target inhibitor treatment in metastatic prostate cancer.

6 days ago

Journal

BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12)

HRD

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients. (PubMed, BMC Med)

The integration of additional biomarker assessments into MTB workflows enhances precision oncology by expanding the pool of patients eligible for targeted therapies.

7 days ago

Journal • Real-world evidence • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker • Biomarker testings

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • FOLR1 ( Folate receptor alpha ) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

HER-2 amplification • HRD • PALB2 mutation • CHEK2 mutation

TruSight Oncology 500 Assay

Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort. (PubMed, Commun Med (Lond))

Although HRD is a biomarker used to determine which cancer patients would benefit from PARP inhibitors, a lack of harmonization of tests to determine HRD status makes it challenging to interpret their results. Our study highlights the use of comprehensive whole genome sequencing analysis to better predict HRD and elucidates genomic mechanisms associated with this phenotype.

8 days ago

Journal • BRCA Biomarker • PARP Biomarker • Pan tumor

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • FANCF (FA complementation group F) • XRCC2 (X-Ray Repair Cross Complementing 2) • FANCC (FA Complementation Group C)

HRD • BRCA wild-type

10d

High-throughput spheroid-based assay for functional breast cancer precision medicine facilitated by deep learning. (PubMed, Commun Med (Lond))

We demonstrate that this assay, guided by automatic spheroid segmentation using deep learning, may report on the tumor's sensitivity to therapies with the potential to be applied to functional precision oncology for breast cancer.

10 days ago

Journal • PARP Biomarker

HRD (Homologous Recombination Deficiency)

HRD

Lynparza (olaparib) • cisplatin

10d

Large-scale regional assessment of surgical volumes and European Society of Gynaecological Oncology quality indicators for ovarian cancer surgery in Italy. (PubMed, Int J Gynecol Cancer)

Ovarian cancer care in Lombardy is partially centralized, with high-volume centers managing most cases and generally adhering to ESGO indicators. However, disparities persist in molecular testing, peri-operative outcome documentation, and equitable access to high-standard care. Strategic investments in diagnostics, referral networks, and data infrastructure are essential to optimize regional outcomes.

10 days ago

Journal • BRCA Biomarker

HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)

HRD

10d

Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers. (PubMed, Clin Transl Med)

In conclusion, bevacizumab remains an integral component of OC treatment. Future progress will depend on biomarker-driven, prospectively designed clinical trials and the integration of multi-omic data and machine learning approaches to enable precision application of anti-angiogenic strategies, maximising clinical benefit while minimising toxicity.

10 days ago

Clinical data • Review • Journal • PARP Biomarker • IO biomarker

TP53 (Tumor protein P53) • HRD (Homologous Recombination Deficiency) • IL6 (Interleukin 6) • CHI3L1 (Chitinase 3-like 1) • ADAM17 (ADAM Metallopeptidase Domain 17)

TP53 mutation • HRD

Avastin (bevacizumab)

10d

Apoptosis of Mesothelial Cells Is Associated with the Pattern of Peritoneal Metastases in Ovarian Cancer. (PubMed, Cancers (Basel))

These findings highlight mesothelial apoptosis as a relevant process in peritoneal dissemination. Further studies are needed to clarify its role in ovarian cancer progression.

10 days ago

Journal • BRCA Biomarker

HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)

HRD • BRCA mutation

11d

Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility. (PubMed, Br J Cancer)

Our findings support the use of multimodal ctDNA profiling as a non-invasive approach to identify HRD in prostate cancer. The integration of mutation, genomic instability, and fragmentomic features provides a broader functional view of HRD and may enhance patient stratification for targeted therapies.

11 days ago

Journal • BRCA Biomarker • PARP Biomarker • Circulating tumor DNA

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • RB1 (RB Transcriptional Corepressor 1)

HRD